Global (United States, European Union and China) Antifibrinolytic Drugs

Antifibrinolytic Drugs Comprehensive Study by Drug Type (Amicar, Aminocaproic acid, Aprotinin, Cyklokapron, Fibrinogen, human, Lysteda, RiaSTAP, Tranexamic acid injection, Tranexamic acid oral, Trasylol), End-users (Hospitals, Ambulatory Surgical Centers, Clinics, Healthcare Specialty processes, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Indications (Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders), Hereditary angioedema, Fibrinolytic response testing, Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)) Players and Region - Global Market Outlook to 2028

Antifibrinolytic Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Antifibrinolytic Drugs Market Scope
Antifibrinolytic drugs are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the breakdown of blood clots. It is used for treatment for hemophilia, in surgical procedures to prevent excessive blood loss, and for heavy menstrual bleeding. The commonly used United States Food and Drugs Administration (FDA)-approved antifibrinolytics include tranexamic acid, aprotinin, and aminocaproic acid.



The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Antifibrinolytic Drugs market throughout the predicted period.

Akorn Inc. (United States), Amerigen Pharmaceuticals Ltd (United States), Xanodyne Pharmaceuticals Inc (United States), Aurobindo Pharma Ltd. (India), Mylan N.V. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), Cadila Healthcare (India) and Takeda Pharmaceutical Company (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Aurobindo Pharma Ltd. (India), Xanodyne Pharmaceuticals Inc (United States) and ACIC Pharmaceuticals Inc. (Canada).

Segmentation Overview
The study have segmented the market of Global Antifibrinolytic Drugs market and Region with country level break-up.

On the basis of geography, the market of Antifibrinolytic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increased Research and Development Activities

Market Growth Drivers:
Increased in Incidence of Angioedema, Increased Number of Road Accidents and Rise in the Medical Surgeries

Challenges:
Stringent Government Rules and Regulations

Restraints:
High Cost of the Antifibrinolytic Drugs

Opportunities:
Growth in the Geriatric Population and Growing Healthcare Industry Worldwide

Market Leaders and their Expansionary Development Strategies
In March 2019, Aurobindo Pharma through its subsidiary Acrotech Biopharma LLC has completed the acquisition of a portfolio of seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc.
In January 2020, ANI acquires the 23 generic products from Amerigen to expand its commercial offering in the United States.


Key Target Audience
Antifibrinolytic Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Drug Type
  • Amicar
  • Aminocaproic acid
  • Aprotinin
  • Cyklokapron
  • Fibrinogen, human
  • Lysteda
  • RiaSTAP
  • Tranexamic acid injection
  • Tranexamic acid oral
  • Trasylol

By End-users
  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Healthcare Specialty processes
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Indications
  • Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders)
  • Hereditary angioedema
  • Fibrinolytic response testing
  • Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased in Incidence of Angioedema
      • 3.2.2. Increased Number of Road Accidents
      • 3.2.3. Rise in the Medical Surgeries
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antifibrinolytic Drugs, by Drug Type, End-users, Distribution Channel, Indications and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antifibrinolytic Drugs (Value)
      • 5.2.1. Global Antifibrinolytic Drugs by: Drug Type (Value)
        • 5.2.1.1. Amicar
        • 5.2.1.2. Aminocaproic acid
        • 5.2.1.3. Aprotinin
        • 5.2.1.4. Cyklokapron
        • 5.2.1.5. Fibrinogen, human
        • 5.2.1.6. Lysteda
        • 5.2.1.7. RiaSTAP
        • 5.2.1.8. Tranexamic acid injection
        • 5.2.1.9. Tranexamic acid oral
        • 5.2.1.10. Trasylol
      • 5.2.2. Global Antifibrinolytic Drugs by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Clinics
        • 5.2.2.4. Healthcare Specialty processes
        • 5.2.2.5. Others
      • 5.2.3. Global Antifibrinolytic Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Antifibrinolytic Drugs by: Indications (Value)
        • 5.2.4.1. Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders)
        • 5.2.4.2. Hereditary angioedema
        • 5.2.4.3. Fibrinolytic response testing
        • 5.2.4.4. Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)
      • 5.2.5. Global Antifibrinolytic Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antifibrinolytic Drugs (Volume)
      • 5.3.1. Global Antifibrinolytic Drugs by: Drug Type (Volume)
        • 5.3.1.1. Amicar
        • 5.3.1.2. Aminocaproic acid
        • 5.3.1.3. Aprotinin
        • 5.3.1.4. Cyklokapron
        • 5.3.1.5. Fibrinogen, human
        • 5.3.1.6. Lysteda
        • 5.3.1.7. RiaSTAP
        • 5.3.1.8. Tranexamic acid injection
        • 5.3.1.9. Tranexamic acid oral
        • 5.3.1.10. Trasylol
      • 5.3.2. Global Antifibrinolytic Drugs by: End-users (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Ambulatory Surgical Centers
        • 5.3.2.3. Clinics
        • 5.3.2.4. Healthcare Specialty processes
        • 5.3.2.5. Others
      • 5.3.3. Global Antifibrinolytic Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online
        • 5.3.3.4. Others
      • 5.3.4. Global Antifibrinolytic Drugs by: Indications (Volume)
        • 5.3.4.1. Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders)
        • 5.3.4.2. Hereditary angioedema
        • 5.3.4.3. Fibrinolytic response testing
        • 5.3.4.4. Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)
      • 5.3.5. Global Antifibrinolytic Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Antifibrinolytic Drugs (Price)
  • 6. Antifibrinolytic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Akorn Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amerigen Pharmaceuticals Ltd (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Xanodyne Pharmaceuticals Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aurobindo Pharma Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan N.V. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cadila Healthcare (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceutical Company (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Antifibrinolytic Drugs Sale, by Drug Type, End-users, Distribution Channel, Indications and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antifibrinolytic Drugs (Value)
      • 7.2.1. Global Antifibrinolytic Drugs by: Drug Type (Value)
        • 7.2.1.1. Amicar
        • 7.2.1.2. Aminocaproic acid
        • 7.2.1.3. Aprotinin
        • 7.2.1.4. Cyklokapron
        • 7.2.1.5. Fibrinogen, human
        • 7.2.1.6. Lysteda
        • 7.2.1.7. RiaSTAP
        • 7.2.1.8. Tranexamic acid injection
        • 7.2.1.9. Tranexamic acid oral
        • 7.2.1.10. Trasylol
      • 7.2.2. Global Antifibrinolytic Drugs by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Clinics
        • 7.2.2.4. Healthcare Specialty processes
        • 7.2.2.5. Others
      • 7.2.3. Global Antifibrinolytic Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Antifibrinolytic Drugs by: Indications (Value)
        • 7.2.4.1. Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders)
        • 7.2.4.2. Hereditary angioedema
        • 7.2.4.3. Fibrinolytic response testing
        • 7.2.4.4. Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)
      • 7.2.5. Global Antifibrinolytic Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antifibrinolytic Drugs (Volume)
      • 7.3.1. Global Antifibrinolytic Drugs by: Drug Type (Volume)
        • 7.3.1.1. Amicar
        • 7.3.1.2. Aminocaproic acid
        • 7.3.1.3. Aprotinin
        • 7.3.1.4. Cyklokapron
        • 7.3.1.5. Fibrinogen, human
        • 7.3.1.6. Lysteda
        • 7.3.1.7. RiaSTAP
        • 7.3.1.8. Tranexamic acid injection
        • 7.3.1.9. Tranexamic acid oral
        • 7.3.1.10. Trasylol
      • 7.3.2. Global Antifibrinolytic Drugs by: End-users (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Ambulatory Surgical Centers
        • 7.3.2.3. Clinics
        • 7.3.2.4. Healthcare Specialty processes
        • 7.3.2.5. Others
      • 7.3.3. Global Antifibrinolytic Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online
        • 7.3.3.4. Others
      • 7.3.4. Global Antifibrinolytic Drugs by: Indications (Volume)
        • 7.3.4.1. Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders)
        • 7.3.4.2. Hereditary angioedema
        • 7.3.4.3. Fibrinolytic response testing
        • 7.3.4.4. Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)
      • 7.3.5. Global Antifibrinolytic Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Antifibrinolytic Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antifibrinolytic Drugs: by Drug Type(USD Million)
  • Table 2. Antifibrinolytic Drugs Amicar , by Region USD Million (2017-2022)
  • Table 3. Antifibrinolytic Drugs Aminocaproic acid , by Region USD Million (2017-2022)
  • Table 4. Antifibrinolytic Drugs Aprotinin , by Region USD Million (2017-2022)
  • Table 5. Antifibrinolytic Drugs Cyklokapron , by Region USD Million (2017-2022)
  • Table 6. Antifibrinolytic Drugs Fibrinogen, human , by Region USD Million (2017-2022)
  • Table 7. Antifibrinolytic Drugs Lysteda , by Region USD Million (2017-2022)
  • Table 8. Antifibrinolytic Drugs RiaSTAP , by Region USD Million (2017-2022)
  • Table 9. Antifibrinolytic Drugs Tranexamic acid injection , by Region USD Million (2017-2022)
  • Table 10. Antifibrinolytic Drugs Tranexamic acid oral , by Region USD Million (2017-2022)
  • Table 11. Antifibrinolytic Drugs Trasylol , by Region USD Million (2017-2022)
  • Table 12. Antifibrinolytic Drugs: by End-users(USD Million)
  • Table 13. Antifibrinolytic Drugs Hospitals , by Region USD Million (2017-2022)
  • Table 14. Antifibrinolytic Drugs Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 15. Antifibrinolytic Drugs Clinics , by Region USD Million (2017-2022)
  • Table 16. Antifibrinolytic Drugs Healthcare Specialty processes , by Region USD Million (2017-2022)
  • Table 17. Antifibrinolytic Drugs Others , by Region USD Million (2017-2022)
  • Table 18. Antifibrinolytic Drugs: by Distribution Channel(USD Million)
  • Table 19. Antifibrinolytic Drugs Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 20. Antifibrinolytic Drugs Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 21. Antifibrinolytic Drugs Online , by Region USD Million (2017-2022)
  • Table 22. Antifibrinolytic Drugs Others , by Region USD Million (2017-2022)
  • Table 23. Antifibrinolytic Drugs: by Indications(USD Million)
  • Table 24. Antifibrinolytic Drugs Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders) , by Region USD Million (2017-2022)
  • Table 25. Antifibrinolytic Drugs Hereditary angioedema , by Region USD Million (2017-2022)
  • Table 26. Antifibrinolytic Drugs Fibrinolytic response testing , by Region USD Million (2017-2022)
  • Table 27. Antifibrinolytic Drugs Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery) , by Region USD Million (2017-2022)
  • Table 28. South America Antifibrinolytic Drugs, by Country USD Million (2017-2022)
  • Table 29. South America Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 30. South America Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 31. South America Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 32. South America Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 33. Brazil Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 34. Brazil Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 35. Brazil Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 36. Brazil Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 37. Argentina Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 38. Argentina Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 39. Argentina Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 40. Argentina Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 41. Rest of South America Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 42. Rest of South America Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 43. Rest of South America Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 44. Rest of South America Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 45. Asia Pacific Antifibrinolytic Drugs, by Country USD Million (2017-2022)
  • Table 46. Asia Pacific Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 47. Asia Pacific Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 48. Asia Pacific Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 49. Asia Pacific Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 50. China Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 51. China Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 52. China Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 53. China Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 54. Japan Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 55. Japan Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 56. Japan Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 57. Japan Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 58. India Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 59. India Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 60. India Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 61. India Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 62. South Korea Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 63. South Korea Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 64. South Korea Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 65. South Korea Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 66. Taiwan Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 67. Taiwan Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 68. Taiwan Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 69. Taiwan Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 70. Australia Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 71. Australia Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 72. Australia Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 73. Australia Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 74. Rest of Asia-Pacific Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 75. Rest of Asia-Pacific Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 76. Rest of Asia-Pacific Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 77. Rest of Asia-Pacific Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 78. Europe Antifibrinolytic Drugs, by Country USD Million (2017-2022)
  • Table 79. Europe Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 80. Europe Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 81. Europe Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 82. Europe Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 83. Germany Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 84. Germany Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 85. Germany Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 86. Germany Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 87. France Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 88. France Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 89. France Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 90. France Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 91. Italy Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 92. Italy Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 93. Italy Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 94. Italy Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 95. United Kingdom Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 96. United Kingdom Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 97. United Kingdom Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 98. United Kingdom Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 99. Netherlands Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 100. Netherlands Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 101. Netherlands Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 102. Netherlands Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 103. Rest of Europe Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 104. Rest of Europe Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 105. Rest of Europe Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 106. Rest of Europe Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 107. MEA Antifibrinolytic Drugs, by Country USD Million (2017-2022)
  • Table 108. MEA Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 109. MEA Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 110. MEA Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 111. MEA Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 112. Middle East Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 113. Middle East Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 114. Middle East Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 115. Middle East Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 116. Africa Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 117. Africa Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 118. Africa Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 119. Africa Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 120. North America Antifibrinolytic Drugs, by Country USD Million (2017-2022)
  • Table 121. North America Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 122. North America Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 123. North America Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 124. North America Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 125. United States Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 126. United States Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 127. United States Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 128. United States Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 129. Canada Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 130. Canada Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 131. Canada Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 132. Canada Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 133. Mexico Antifibrinolytic Drugs, by Drug Type USD Million (2017-2022)
  • Table 134. Mexico Antifibrinolytic Drugs, by End-users USD Million (2017-2022)
  • Table 135. Mexico Antifibrinolytic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 136. Mexico Antifibrinolytic Drugs, by Indications USD Million (2017-2022)
  • Table 137. Antifibrinolytic Drugs Sales: by Drug Type(K Units)
  • Table 138. Antifibrinolytic Drugs Sales Amicar , by Region K Units (2017-2022)
  • Table 139. Antifibrinolytic Drugs Sales Aminocaproic acid , by Region K Units (2017-2022)
  • Table 140. Antifibrinolytic Drugs Sales Aprotinin , by Region K Units (2017-2022)
  • Table 141. Antifibrinolytic Drugs Sales Cyklokapron , by Region K Units (2017-2022)
  • Table 142. Antifibrinolytic Drugs Sales Fibrinogen, human , by Region K Units (2017-2022)
  • Table 143. Antifibrinolytic Drugs Sales Lysteda , by Region K Units (2017-2022)
  • Table 144. Antifibrinolytic Drugs Sales RiaSTAP , by Region K Units (2017-2022)
  • Table 145. Antifibrinolytic Drugs Sales Tranexamic acid injection , by Region K Units (2017-2022)
  • Table 146. Antifibrinolytic Drugs Sales Tranexamic acid oral , by Region K Units (2017-2022)
  • Table 147. Antifibrinolytic Drugs Sales Trasylol , by Region K Units (2017-2022)
  • Table 148. Antifibrinolytic Drugs Sales: by End-users(K Units)
  • Table 149. Antifibrinolytic Drugs Sales Hospitals , by Region K Units (2017-2022)
  • Table 150. Antifibrinolytic Drugs Sales Ambulatory Surgical Centers , by Region K Units (2017-2022)
  • Table 151. Antifibrinolytic Drugs Sales Clinics , by Region K Units (2017-2022)
  • Table 152. Antifibrinolytic Drugs Sales Healthcare Specialty processes , by Region K Units (2017-2022)
  • Table 153. Antifibrinolytic Drugs Sales Others , by Region K Units (2017-2022)
  • Table 154. Antifibrinolytic Drugs Sales: by Distribution Channel(K Units)
  • Table 155. Antifibrinolytic Drugs Sales Hospital Pharmacies , by Region K Units (2017-2022)
  • Table 156. Antifibrinolytic Drugs Sales Retail Pharmacies , by Region K Units (2017-2022)
  • Table 157. Antifibrinolytic Drugs Sales Online , by Region K Units (2017-2022)
  • Table 158. Antifibrinolytic Drugs Sales Others , by Region K Units (2017-2022)
  • Table 159. Antifibrinolytic Drugs Sales: by Indications(K Units)
  • Table 160. Antifibrinolytic Drugs Sales Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders) , by Region K Units (2017-2022)
  • Table 161. Antifibrinolytic Drugs Sales Hereditary angioedema , by Region K Units (2017-2022)
  • Table 162. Antifibrinolytic Drugs Sales Fibrinolytic response testing , by Region K Units (2017-2022)
  • Table 163. Antifibrinolytic Drugs Sales Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery) , by Region K Units (2017-2022)
  • Table 164. South America Antifibrinolytic Drugs Sales, by Country K Units (2017-2022)
  • Table 165. South America Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 166. South America Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 167. South America Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 168. South America Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 169. Brazil Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 170. Brazil Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 171. Brazil Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 172. Brazil Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 173. Argentina Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 174. Argentina Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 175. Argentina Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 176. Argentina Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 177. Rest of South America Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 178. Rest of South America Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 179. Rest of South America Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 180. Rest of South America Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 181. Asia Pacific Antifibrinolytic Drugs Sales, by Country K Units (2017-2022)
  • Table 182. Asia Pacific Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 183. Asia Pacific Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 184. Asia Pacific Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 185. Asia Pacific Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 186. China Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 187. China Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 188. China Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 189. China Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 190. Japan Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 191. Japan Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 192. Japan Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 193. Japan Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 194. India Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 195. India Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 196. India Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 197. India Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 198. South Korea Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 199. South Korea Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 200. South Korea Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 201. South Korea Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 202. Taiwan Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 203. Taiwan Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 204. Taiwan Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 205. Taiwan Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 206. Australia Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 207. Australia Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 208. Australia Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 209. Australia Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 210. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 211. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 212. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 213. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 214. Europe Antifibrinolytic Drugs Sales, by Country K Units (2017-2022)
  • Table 215. Europe Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 216. Europe Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 217. Europe Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 218. Europe Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 219. Germany Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 220. Germany Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 221. Germany Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 222. Germany Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 223. France Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 224. France Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 225. France Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 226. France Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 227. Italy Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 228. Italy Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 229. Italy Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 230. Italy Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 231. United Kingdom Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 232. United Kingdom Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 233. United Kingdom Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 234. United Kingdom Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 235. Netherlands Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 236. Netherlands Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 237. Netherlands Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 238. Netherlands Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 239. Rest of Europe Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 240. Rest of Europe Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 241. Rest of Europe Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 242. Rest of Europe Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 243. MEA Antifibrinolytic Drugs Sales, by Country K Units (2017-2022)
  • Table 244. MEA Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 245. MEA Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 246. MEA Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 247. MEA Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 248. Middle East Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 249. Middle East Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 250. Middle East Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 251. Middle East Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 252. Africa Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 253. Africa Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 254. Africa Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 255. Africa Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 256. North America Antifibrinolytic Drugs Sales, by Country K Units (2017-2022)
  • Table 257. North America Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 258. North America Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 259. North America Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 260. North America Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 261. United States Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 262. United States Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 263. United States Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 264. United States Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 265. Canada Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 266. Canada Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 267. Canada Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 268. Canada Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 269. Mexico Antifibrinolytic Drugs Sales, by Drug Type K Units (2017-2022)
  • Table 270. Mexico Antifibrinolytic Drugs Sales, by End-users K Units (2017-2022)
  • Table 271. Mexico Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 272. Mexico Antifibrinolytic Drugs Sales, by Indications K Units (2017-2022)
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Company Basic Information, Sales Area and Its Competitors
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Company Basic Information, Sales Area and Its Competitors
  • Table 281. Company Basic Information, Sales Area and Its Competitors
  • Table 282. Antifibrinolytic Drugs: by Drug Type(USD Million)
  • Table 283. Antifibrinolytic Drugs Amicar , by Region USD Million (2023-2028)
  • Table 284. Antifibrinolytic Drugs Aminocaproic acid , by Region USD Million (2023-2028)
  • Table 285. Antifibrinolytic Drugs Aprotinin , by Region USD Million (2023-2028)
  • Table 286. Antifibrinolytic Drugs Cyklokapron , by Region USD Million (2023-2028)
  • Table 287. Antifibrinolytic Drugs Fibrinogen, human , by Region USD Million (2023-2028)
  • Table 288. Antifibrinolytic Drugs Lysteda , by Region USD Million (2023-2028)
  • Table 289. Antifibrinolytic Drugs RiaSTAP , by Region USD Million (2023-2028)
  • Table 290. Antifibrinolytic Drugs Tranexamic acid injection , by Region USD Million (2023-2028)
  • Table 291. Antifibrinolytic Drugs Tranexamic acid oral , by Region USD Million (2023-2028)
  • Table 292. Antifibrinolytic Drugs Trasylol , by Region USD Million (2023-2028)
  • Table 293. Antifibrinolytic Drugs: by End-users(USD Million)
  • Table 294. Antifibrinolytic Drugs Hospitals , by Region USD Million (2023-2028)
  • Table 295. Antifibrinolytic Drugs Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 296. Antifibrinolytic Drugs Clinics , by Region USD Million (2023-2028)
  • Table 297. Antifibrinolytic Drugs Healthcare Specialty processes , by Region USD Million (2023-2028)
  • Table 298. Antifibrinolytic Drugs Others , by Region USD Million (2023-2028)
  • Table 299. Antifibrinolytic Drugs: by Distribution Channel(USD Million)
  • Table 300. Antifibrinolytic Drugs Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 301. Antifibrinolytic Drugs Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 302. Antifibrinolytic Drugs Online , by Region USD Million (2023-2028)
  • Table 303. Antifibrinolytic Drugs Others , by Region USD Million (2023-2028)
  • Table 304. Antifibrinolytic Drugs: by Indications(USD Million)
  • Table 305. Antifibrinolytic Drugs Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders) , by Region USD Million (2023-2028)
  • Table 306. Antifibrinolytic Drugs Hereditary angioedema , by Region USD Million (2023-2028)
  • Table 307. Antifibrinolytic Drugs Fibrinolytic response testing , by Region USD Million (2023-2028)
  • Table 308. Antifibrinolytic Drugs Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery) , by Region USD Million (2023-2028)
  • Table 309. South America Antifibrinolytic Drugs, by Country USD Million (2023-2028)
  • Table 310. South America Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 311. South America Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 312. South America Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 313. South America Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 314. Brazil Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 315. Brazil Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 316. Brazil Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 317. Brazil Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 318. Argentina Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 319. Argentina Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 320. Argentina Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 321. Argentina Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 322. Rest of South America Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 323. Rest of South America Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 324. Rest of South America Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 325. Rest of South America Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 326. Asia Pacific Antifibrinolytic Drugs, by Country USD Million (2023-2028)
  • Table 327. Asia Pacific Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 328. Asia Pacific Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 329. Asia Pacific Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 330. Asia Pacific Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 331. China Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 332. China Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 333. China Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 334. China Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 335. Japan Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 336. Japan Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 337. Japan Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 338. Japan Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 339. India Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 340. India Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 341. India Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 342. India Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 343. South Korea Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 344. South Korea Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 345. South Korea Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 346. South Korea Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 347. Taiwan Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 348. Taiwan Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 349. Taiwan Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 350. Taiwan Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 351. Australia Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 352. Australia Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 353. Australia Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 354. Australia Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 355. Rest of Asia-Pacific Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 356. Rest of Asia-Pacific Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 357. Rest of Asia-Pacific Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 358. Rest of Asia-Pacific Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 359. Europe Antifibrinolytic Drugs, by Country USD Million (2023-2028)
  • Table 360. Europe Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 361. Europe Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 362. Europe Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 363. Europe Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 364. Germany Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 365. Germany Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 366. Germany Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 367. Germany Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 368. France Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 369. France Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 370. France Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 371. France Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 372. Italy Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 373. Italy Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 374. Italy Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 375. Italy Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 376. United Kingdom Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 377. United Kingdom Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 378. United Kingdom Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 379. United Kingdom Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 380. Netherlands Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 381. Netherlands Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 382. Netherlands Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 383. Netherlands Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 384. Rest of Europe Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 385. Rest of Europe Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 386. Rest of Europe Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 387. Rest of Europe Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 388. MEA Antifibrinolytic Drugs, by Country USD Million (2023-2028)
  • Table 389. MEA Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 390. MEA Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 391. MEA Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 392. MEA Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 393. Middle East Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 394. Middle East Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 395. Middle East Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 396. Middle East Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 397. Africa Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 398. Africa Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 399. Africa Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 400. Africa Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 401. North America Antifibrinolytic Drugs, by Country USD Million (2023-2028)
  • Table 402. North America Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 403. North America Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 404. North America Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 405. North America Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 406. United States Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 407. United States Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 408. United States Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 409. United States Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 410. Canada Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 411. Canada Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 412. Canada Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 413. Canada Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 414. Mexico Antifibrinolytic Drugs, by Drug Type USD Million (2023-2028)
  • Table 415. Mexico Antifibrinolytic Drugs, by End-users USD Million (2023-2028)
  • Table 416. Mexico Antifibrinolytic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 417. Mexico Antifibrinolytic Drugs, by Indications USD Million (2023-2028)
  • Table 418. Antifibrinolytic Drugs Sales: by Drug Type(K Units)
  • Table 419. Antifibrinolytic Drugs Sales Amicar , by Region K Units (2023-2028)
  • Table 420. Antifibrinolytic Drugs Sales Aminocaproic acid , by Region K Units (2023-2028)
  • Table 421. Antifibrinolytic Drugs Sales Aprotinin , by Region K Units (2023-2028)
  • Table 422. Antifibrinolytic Drugs Sales Cyklokapron , by Region K Units (2023-2028)
  • Table 423. Antifibrinolytic Drugs Sales Fibrinogen, human , by Region K Units (2023-2028)
  • Table 424. Antifibrinolytic Drugs Sales Lysteda , by Region K Units (2023-2028)
  • Table 425. Antifibrinolytic Drugs Sales RiaSTAP , by Region K Units (2023-2028)
  • Table 426. Antifibrinolytic Drugs Sales Tranexamic acid injection , by Region K Units (2023-2028)
  • Table 427. Antifibrinolytic Drugs Sales Tranexamic acid oral , by Region K Units (2023-2028)
  • Table 428. Antifibrinolytic Drugs Sales Trasylol , by Region K Units (2023-2028)
  • Table 429. Antifibrinolytic Drugs Sales: by End-users(K Units)
  • Table 430. Antifibrinolytic Drugs Sales Hospitals , by Region K Units (2023-2028)
  • Table 431. Antifibrinolytic Drugs Sales Ambulatory Surgical Centers , by Region K Units (2023-2028)
  • Table 432. Antifibrinolytic Drugs Sales Clinics , by Region K Units (2023-2028)
  • Table 433. Antifibrinolytic Drugs Sales Healthcare Specialty processes , by Region K Units (2023-2028)
  • Table 434. Antifibrinolytic Drugs Sales Others , by Region K Units (2023-2028)
  • Table 435. Antifibrinolytic Drugs Sales: by Distribution Channel(K Units)
  • Table 436. Antifibrinolytic Drugs Sales Hospital Pharmacies , by Region K Units (2023-2028)
  • Table 437. Antifibrinolytic Drugs Sales Retail Pharmacies , by Region K Units (2023-2028)
  • Table 438. Antifibrinolytic Drugs Sales Online , by Region K Units (2023-2028)
  • Table 439. Antifibrinolytic Drugs Sales Others , by Region K Units (2023-2028)
  • Table 440. Antifibrinolytic Drugs Sales: by Indications(K Units)
  • Table 441. Antifibrinolytic Drugs Sales Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders) , by Region K Units (2023-2028)
  • Table 442. Antifibrinolytic Drugs Sales Hereditary angioedema , by Region K Units (2023-2028)
  • Table 443. Antifibrinolytic Drugs Sales Fibrinolytic response testing , by Region K Units (2023-2028)
  • Table 444. Antifibrinolytic Drugs Sales Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery) , by Region K Units (2023-2028)
  • Table 445. South America Antifibrinolytic Drugs Sales, by Country K Units (2023-2028)
  • Table 446. South America Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 447. South America Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 448. South America Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 449. South America Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 450. Brazil Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 451. Brazil Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 452. Brazil Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 453. Brazil Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 454. Argentina Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 455. Argentina Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 456. Argentina Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 457. Argentina Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 458. Rest of South America Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 459. Rest of South America Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 460. Rest of South America Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 461. Rest of South America Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 462. Asia Pacific Antifibrinolytic Drugs Sales, by Country K Units (2023-2028)
  • Table 463. Asia Pacific Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 464. Asia Pacific Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 465. Asia Pacific Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 466. Asia Pacific Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 467. China Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 468. China Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 469. China Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 470. China Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 471. Japan Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 472. Japan Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 473. Japan Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 474. Japan Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 475. India Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 476. India Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 477. India Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 478. India Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 479. South Korea Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 480. South Korea Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 481. South Korea Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 482. South Korea Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 483. Taiwan Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 484. Taiwan Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 485. Taiwan Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 486. Taiwan Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 487. Australia Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 488. Australia Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 489. Australia Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 490. Australia Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 491. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 492. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 493. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 494. Rest of Asia-Pacific Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 495. Europe Antifibrinolytic Drugs Sales, by Country K Units (2023-2028)
  • Table 496. Europe Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 497. Europe Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 498. Europe Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 499. Europe Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 500. Germany Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 501. Germany Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 502. Germany Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 503. Germany Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 504. France Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 505. France Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 506. France Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 507. France Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 508. Italy Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 509. Italy Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 510. Italy Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 511. Italy Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 512. United Kingdom Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 513. United Kingdom Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 514. United Kingdom Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 515. United Kingdom Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 516. Netherlands Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 517. Netherlands Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 518. Netherlands Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 519. Netherlands Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 520. Rest of Europe Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 521. Rest of Europe Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 522. Rest of Europe Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 523. Rest of Europe Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 524. MEA Antifibrinolytic Drugs Sales, by Country K Units (2023-2028)
  • Table 525. MEA Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 526. MEA Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 527. MEA Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 528. MEA Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 529. Middle East Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 530. Middle East Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 531. Middle East Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 532. Middle East Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 533. Africa Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 534. Africa Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 535. Africa Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 536. Africa Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 537. North America Antifibrinolytic Drugs Sales, by Country K Units (2023-2028)
  • Table 538. North America Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 539. North America Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 540. North America Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 541. North America Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 542. United States Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 543. United States Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 544. United States Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 545. United States Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 546. Canada Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 547. Canada Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 548. Canada Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 549. Canada Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 550. Mexico Antifibrinolytic Drugs Sales, by Drug Type K Units (2023-2028)
  • Table 551. Mexico Antifibrinolytic Drugs Sales, by End-users K Units (2023-2028)
  • Table 552. Mexico Antifibrinolytic Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 553. Mexico Antifibrinolytic Drugs Sales, by Indications K Units (2023-2028)
  • Table 554. Research Programs/Design for This Report
  • Table 555. Key Data Information from Secondary Sources
  • Table 556. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antifibrinolytic Drugs: by Drug Type USD Million (2017-2022)
  • Figure 5. Global Antifibrinolytic Drugs: by End-users USD Million (2017-2022)
  • Figure 6. Global Antifibrinolytic Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Antifibrinolytic Drugs: by Indications USD Million (2017-2022)
  • Figure 8. South America Antifibrinolytic Drugs Share (%), by Country
  • Figure 9. Asia Pacific Antifibrinolytic Drugs Share (%), by Country
  • Figure 10. Europe Antifibrinolytic Drugs Share (%), by Country
  • Figure 11. MEA Antifibrinolytic Drugs Share (%), by Country
  • Figure 12. North America Antifibrinolytic Drugs Share (%), by Country
  • Figure 13. Global Antifibrinolytic Drugs: by Drug Type K Units (2017-2022)
  • Figure 14. Global Antifibrinolytic Drugs: by End-users K Units (2017-2022)
  • Figure 15. Global Antifibrinolytic Drugs: by Distribution Channel K Units (2017-2022)
  • Figure 16. Global Antifibrinolytic Drugs: by Indications K Units (2017-2022)
  • Figure 17. South America Antifibrinolytic Drugs Share (%), by Country
  • Figure 18. Asia Pacific Antifibrinolytic Drugs Share (%), by Country
  • Figure 19. Europe Antifibrinolytic Drugs Share (%), by Country
  • Figure 20. MEA Antifibrinolytic Drugs Share (%), by Country
  • Figure 21. North America Antifibrinolytic Drugs Share (%), by Country
  • Figure 22. Global Antifibrinolytic Drugs share by Players 2022 (%)
  • Figure 23. Global Antifibrinolytic Drugs share by Players (Top 3) 2022(%)
  • Figure 24. Global Antifibrinolytic Drugs share by Players (Top 5) 2022(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Akorn Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Akorn Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Amerigen Pharmaceuticals Ltd (United States) Revenue, Net Income and Gross profit
  • Figure 29. Amerigen Pharmaceuticals Ltd (United States) Revenue: by Geography 2022
  • Figure 30. Xanodyne Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 31. Xanodyne Pharmaceuticals Inc (United States) Revenue: by Geography 2022
  • Figure 32. Aurobindo Pharma Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 33. Aurobindo Pharma Ltd. (India) Revenue: by Geography 2022
  • Figure 34. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi S.A. (France) Revenue: by Geography 2022
  • Figure 40. Cadila Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 41. Cadila Healthcare (India) Revenue: by Geography 2022
  • Figure 42. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 43. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2022
  • Figure 44. Global Antifibrinolytic Drugs: by Drug Type USD Million (2023-2028)
  • Figure 45. Global Antifibrinolytic Drugs: by End-users USD Million (2023-2028)
  • Figure 46. Global Antifibrinolytic Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 47. Global Antifibrinolytic Drugs: by Indications USD Million (2023-2028)
  • Figure 48. South America Antifibrinolytic Drugs Share (%), by Country
  • Figure 49. Asia Pacific Antifibrinolytic Drugs Share (%), by Country
  • Figure 50. Europe Antifibrinolytic Drugs Share (%), by Country
  • Figure 51. MEA Antifibrinolytic Drugs Share (%), by Country
  • Figure 52. North America Antifibrinolytic Drugs Share (%), by Country
  • Figure 53. Global Antifibrinolytic Drugs: by Drug Type K Units (2023-2028)
  • Figure 54. Global Antifibrinolytic Drugs: by End-users K Units (2023-2028)
  • Figure 55. Global Antifibrinolytic Drugs: by Distribution Channel K Units (2023-2028)
  • Figure 56. Global Antifibrinolytic Drugs: by Indications K Units (2023-2028)
  • Figure 57. South America Antifibrinolytic Drugs Share (%), by Country
  • Figure 58. Asia Pacific Antifibrinolytic Drugs Share (%), by Country
  • Figure 59. Europe Antifibrinolytic Drugs Share (%), by Country
  • Figure 60. MEA Antifibrinolytic Drugs Share (%), by Country
  • Figure 61. North America Antifibrinolytic Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Akorn Inc. (United States)
  • Amerigen Pharmaceuticals Ltd (United States)
  • Xanodyne Pharmaceuticals Inc (United States)
  • Aurobindo Pharma Ltd. (India)
  • Mylan N.V. (United States)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • Cadila Healthcare (India)
  • Takeda Pharmaceutical Company (Japan)
Additional players considered in the study are as follows:
Aurobindo Pharma Ltd. (India) , Xanodyne Pharmaceuticals Inc (United States) , ACIC Pharmaceuticals Inc. (Canada)
Select User Access Type

Key Highlights of Report


May 2023 237 Pages 86 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Antifibrinolytic Drugs Quantitative research analysis
Global (United States, European Union and China) Antifibrinolytic Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Antifibrinolytic Drugs study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Antifibrinolytic Drugs Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Antifibrinolytic Drugs market is expected to see growth rate of xx%.
The Antifibrinolytic Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global (United States, European Union and China) Antifibrinolytic Drugs Report?

Have a Query? Click Here

Other Related Reports

Botulism Illness Comprehensive Study by Type (Antibiotics, Antitoxins, Other), Application (Hospitals, Clinics, Other), Distribution Channel (OTC, Prescribed) Players and Region - Global Market Outlo...
$ 3500
Drug Eluting Beads Comprehensive Study by Type (LC Beads, QuadraSpheres, Oncozene Beads), Application (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Research Centers), Drug (Doxorubici...
$ 3800
Breast Cancer Monoclonal Antibodies Comprehensive Study by Type (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Application (Hospitals, Retail Pharm...
$ 3500
Sotalol Drug Comprehensive Study by Application (Ventricular Arrhythmias, Atrial Fibrillation/Flutter, Supraventricular Arrhythmias), Distribution Channel (Sales Channel Hospital Pharmacies, Drug Sto...
$ 3650
Eye Infections Treatment Comprehensive Study by Type (Gels and Creams, Eye Drops, Drug), Application (Ophthalmology Clinics, Hospitals, Others), Eye Infection (Conjunctivitis or Pink Eye, Viral Kerat...
$ 3750
Allopurinol Tablets Comprehensive Study by Type (100 mg, 300 mg), Application (Healthcare Industry, Hospitals), Distribution Channel (Hospitals, Pharma Retail, Clinics, Others), Side Effects (Nausea,...
$ 3350